<DOC>
	<DOC>NCT00428350</DOC>
	<brief_summary>The primary objective of the study is to evaluate the efficacy of quetiapine fumarate (Seroquel) with daily dose 600mg-750mg used as mono-therapy in the treatment of acute schizophrenic patients by evaluation of the change from baseline in PANSS total score at Day 56 using the last observation carried forward (LOCF) method.</brief_summary>
	<brief_title>Study of Efficacy and Safety of Seroquel (Quetiapine Fumarate) as Mono-Therapy for Acute Schizophrenic</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Provision of written informed consent for study participation before initiation of any study related procedures, signed by the patient's legal guardian Female and/or male, aged between 18 and 60 years (inclusive) Is hospitalised in a psychiatric unit with an acute episode of schizophrenia defined by CCMD3 criteria as one of the following: [20.1] paranoid schizophrenia, [20.2] hebephrenic schizophrenia, [20.3] catatonic schizophrenia, [20.5] undifferentiated schizophrenia CCMD3 diagnosis of mental retardation Psychosis judged to be the direct physiological effect of an abused medication or substance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>